Roche: Tecentriq proves promising in liver cancer
(CercleFinance.com) - Roche today presented "promising" results from a Phase Ib study evaluating the efficacy and safety of its immunotherapy Tecentriq, in combination with Avastin, as a treatment for unresectable hepatocellular carcinoma, the most common form of liver cancer.
Data from a non-randomised trial showed clinically meaningful and durable responses after a median follow-up of 12.4 months, with a confirmed objective response rate of 36%, Roche said.
The Swiss drugmaker said it was "encouraged" by these latest results for a disease for which the unmet medical need is particularly great.
"These data strengthen our belief in the combination of Tecentriq and Avastin in this common form of liver cancer and we look forward to the results from our Phase III study," said Sandra Horning, Roche's chief medical officer.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
Data from a non-randomised trial showed clinically meaningful and durable responses after a median follow-up of 12.4 months, with a confirmed objective response rate of 36%, Roche said.
The Swiss drugmaker said it was "encouraged" by these latest results for a disease for which the unmet medical need is particularly great.
"These data strengthen our belief in the combination of Tecentriq and Avastin in this common form of liver cancer and we look forward to the results from our Phase III study," said Sandra Horning, Roche's chief medical officer.
Copyright (c) 2019 CercleFinance.com. All rights reserved.